Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kura Oncology (NASDAQ:KURA)

Core Viewpoint - Kura Oncology, Inc. has granted inducement awards in the form of nonstatutory stock options to new employees as part of its 2023 Inducement Option Plan, aimed at enhancing employee retention and attracting talent [1][2]. Group 1: Inducement Awards - The Compensation Committee granted stock options to purchase 44,700 shares of common stock to four new employees [1]. - Each stock option has an exercise price of $8.68 per share, which is the closing price of the Company's common stock on March 2, 2026 [2]. - The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remaining shares vesting monthly over the following 36 months [2]. Group 2: Compliance and Terms - The stock options are granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement material to the new employees' employment [1]. - The options are subject to the terms and conditions of the Company's 2023 Inducement Option Plan and an applicable stock option agreement [2].